Oncotarget

Priority Research Perspective:

Sexually dimorphic tumor suppression by small mitochondrial Arf

Jolieke G. van Oosterwijk, Heather Tillman, Charles J. Sherr _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2019; 10:1235-1237. https://doi.org/10.18632/oncotarget.26651

Metrics: PDF 113 views  |   HTML 165 views  |   ?  


Abstract

Jolieke G. van Oosterwijk1,3, Heather Tillman2 and Charles J. Sherr1,3

1 Department of Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA

2 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA

3 Howard Hughes Medical Institute, St. Jude Children’s Research Hospital, Memphis, TN, USA

Correspondence to:

Charles J. Sherr, email: sherr@stjude.org

Keywords: Arf tumor suppressor; small mitochondrial Arf (smArf); smArf sexual dimorphism

Received: January 02, 2019    Accepted: January 21, 2019    Published: February 08, 2019

Abstract

Internal translational initiation of the mRNA encoding the Arf tumor suppressor yields an N-terminally truncated small Arf protein (smArf) that lacks amino acid residues required for Mdm2 binding and p53 activation. Here, we report that female, but not male, mice engineered to produce only smArf in lieu of the full-length Arf protein retain residual, sexually dimorphic tumor suppressive activity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26651